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Abstract 
Nicotinic acetylcholine receptors (nAChRs) play essential roles in transmitting acetylcholine-mediated 
neural signals across synapses and neuromuscular junctions, and are also closely linked to various 
diseases and clinical conditions. Therefore, novel nAChR-specific compounds have great potential for 
both neuroscience research and clinical applications. Conotoxins, the peptide neurotoxins produced by 
cone snails, are a rich reservoir of novel ligands that target receptors, ion channels and transporters in the 
nervous system. From the venom of Conus generalis, we identified a novel dimeric nAChR-inhibiting αD-
conotoxin GeXXA. By solving the crystal structure and performing structure-guided dissection of this 
toxin, we demonstrated that the monomeric C-terminal domain of αD-GeXXA, GeXXA-CTD, retains 
inhibitory activity against the α9α10 nAChR subtype. Furthermore, we identified that His7 of the rat α10 
nAChR subunit determines the species preference of αD-GeXXA, and is probably part of the binding site 
of this toxin. These results together suggest that αD-GeXXA cooperatively binds to two inter-subunit 
interfaces on the top surface of nAChR, thus allosterically disturbing the opening of the receptor. The 
novel antagonistic mechanism of αD-GeXXA via a new binding site on nAChRs provides a valuable basis 
for the rational design of new nAChR-targeting compounds. 
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Conotoxin αD-GeXXA utilizes 
a novel strategy to antagonize 
nicotinic acetylcholine receptors
Shaoqiong Xu1,*, Tianlong Zhang2,*, Shiva N. Kompella3,*, Mengdi Yan1, Aiping Lu1, 
Yanfang Wang1, Xiaoxia Shao1, Chengwu Chi1,2, David J. Adams3, Jianping Ding2 & 
Chunguang Wang1
Nicotinic acetylcholine receptors (nAChRs) play essential roles in transmitting acetylcholine-mediated 
neural signals across synapses and neuromuscular junctions, and are also closely linked to various 
diseases and clinical conditions. Therefore, novel nAChR-specific compounds have great potential 
for both neuroscience research and clinical applications. Conotoxins, the peptide neurotoxins 
produced by cone snails, are a rich reservoir of novel ligands that target receptors, ion channels and 
transporters in the nervous system. From the venom of Conus generalis, we identified a novel dimeric 
nAChR-inhibiting αD-conotoxin GeXXA. By solving the crystal structure and performing structure-
guided dissection of this toxin, we demonstrated that the monomeric C-terminal domain of αD-
GeXXA, GeXXA-CTD, retains inhibitory activity against the α9α10 nAChR subtype. Furthermore, we 
identified that His7 of the rat α10 nAChR subunit determines the species preference of αD-GeXXA, 
and is probably part of the binding site of this toxin. These results together suggest that αD-GeXXA 
cooperatively binds to two inter-subunit interfaces on the top surface of nAChR, thus allosterically 
disturbing the opening of the receptor. The novel antagonistic mechanism of αD-GeXXA via a new 
binding site on nAChRs provides a valuable basis for the rational design of new nAChR-targeting 
compounds.
Acetylcholine (ACh) is an important neurotransmitter in nervous signal transmission. For the 
ACh-mediated nerve signals to transmit across synapses or neuromuscular junction (NMJ), ACh is 
released from the pre-synaptic terminal, and then binds to the extracellular domain of post-synaptic nic-
otinic acetylcholine receptors (nAChRs), which allosterically leads to the opening of the transmembrane 
channel of nAChRs to mediate a cationic current1. Because of this fundamental role of nAChRs in nerve 
signal transmission, malfunction of nAChRs is linked to various diseases including myasthenia gravis2.
nAChRs are composed of five homologous α - (α 1-α 10), β - (β 1-β 4), δ -, ε - or γ -subunits1. The 
muscle-type nAChR has a heteropentameric (α 1)2β 1δ γ or (α 1)2β 1δ ε composition, whereas neu-
ronal nAChRs are either heteropentameric of two α subunits and three auxiliary α or β subunits or a 
homopentameric α 7 subtype. Based on crystal structures of ACh binding proteins (AChBPs) that are 
structurally homologous to the extracellular domain of nAChRs3,4, ACh binds to the interface between a 
principal (+ ) side of the α subunit and a complementary (− ) side of the neighbouring subunit. Thus, the 
pentameric nAChRs often have two ACh binding sites, the gating mechanism of which is still unknown. 
Therefore, novel nAChR-specific compounds have great potential for both neuroscience research and 
clinical applications.
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On the other hand, nAChRs are also the targets of various naturally occurring neurotoxins. These 
nAChR-targeting toxins have not only facilitated structural and functional studies of nAChRs, but also 
serve as lead compounds in nAChR-targeting drug development5. Among those natural toxins, the pep-
tide neurotoxins produced by marine cone snails, generally termed conotoxins, are of particular interest6. 
Several families of conotoxins with different sequences and chemical structures (α -, Ψ -, α B-, α D-, α C-, 
and α S-conotoxins) can target nAChRs, with α -conotoxins being the most extensively studied ones7–11. 
Whilst Ψ -conotoxins are competitive inhibitors of nAChRs via binding to the ACh-binding site12,13, Ψ - 
and α D-conotoxins can inhibit nAChRs noncompetitively, at yet unknown binding sites8,14. In particular, 
α D-conotoxins occur naturally as a dimer with complex disulfide connections (10 disulfide bonds per 
dimer)8. This makes the structural study of the α D-conotoxin family more challenging and the molecular 
mechanism of their function more intriguing.
Here we present the crystal structure and electrophysiological activity profile of a dimeric 
α D-conotoxin GeXXA. Based on these results, we elucidated the mechanism of action of this dimeric 
conotoxin. Furthermore, we identified the binding site of this conotoxin on nAChRs, which is clearly 
different from that of ACh. Together, our results establish a new antagonistic mechanism at nAChRs, 
providing a valuable basis for the rational design of novel nAChR-targeting compounds.
Results and Discussion
Identification of αD-conotoxin GeXXA. We identified and isolated a novel α D-conotoxin GeXXA 
from the venom of Conus generalis (Fig 1A). Reduction of this toxin shifted its molecular weight from 
11249.0 Da to 5635.0 Da, and alkylation with N-ethylmaleimide (NEM) increased its weight to 6885.0 Da 
(Fig. S1A). These results indicate this toxin contains 10 Cys residues per peptide and exists as a homod-
imer with inter-chain disulfide bond(s). N-terminal sequencing and subsequent cDNA cloning of this 
toxin revealed that each peptide chain of α D-GeXXA comprises 50 amino acid residues sharing high 
sequence homology with other known α D-conotoxins (Fig. S1).
As α D-conotoxins can act as noncompetitive inhibitors of nAChRs8, we first tested the effects of 
α D-GeXXA on ACh-evoked currents mediated by different nAChR subtypes expressed in Xenopus 
oocytes. Our electrophysiology data showed that α D-GeXXA has strong inhibitory activity on α 9α 10, 
α 7 and α 3β 2 subtypes, moderate inhibitory activity on α 3β 4 and α 1β 1δ ε subtypes, and weak activity on 
α 4β 2 and α 4β 4 subtypes (Fig. 1C and Table 1). In particular, α D-GeXXA is most potent against human 
α 9α 10 subtype with an IC50 of 28 nM.
Crystal structure of αD-GeXXA. To gain insight into its biological function, we determined the 
crystal structure of native α D-GeXXA using ab initio methods15 and refined it to 1.5 Å resolution (Table 
S1 and Fig.  2). There is one conotoxin homodimer with a pseudo two-fold symmetry per asymmetric 
unit. Each peptide chain consists of an N-terminal domain (NTD, residues 1–20) and a C-terminal 
domain (CTD, residues 21–50). The NTD comprises an N-terminal loop and a β -strand, and the CTD 
assumes several extended loop conformations. The dimerization involves mainly the N-terminal loops 
and β -strands of the NTDs, which is further stabilized by two inter-chain disulfide bonds between Cys6 
of one chain and Cys18 of the other. There are three disulfide bonds (Cys24-Cys36, Cys29-Cys46 and 
Cys34-Cys48) in the CTD, making the CTD adopt a compact structure. The two CTDs flank the dimeric 
NTDs, and the relative conformation of the NTD and the CTD is stabilized by a disulfide bond between 
Cys19 and Cys28 (Fig. 2).
Preparation of monomeric GeXXA-CTD. Interestingly, the CTD of α D-GeXXA adopts a canonical 
inhibitory cystine knot (ICK) disulfide linkage, as observed in many 6-Cys-residue-containing bioactive 
peptides, including several families of conotoxins16. This observation prompted us to speculate that the 
CTD of α D-GeXXA alone may exhibit inhibitory activity against nAChRs. To obtain an isolated CTD, 
we first synthesized a peptide of residues 21–50, with Cys28 replaced by Ser and the thiol groups of both 
Cys24 and Cys36 protected by the acetamidomethyl groups (Acm) (Fig. S2A). Oxidation of the syn-
thetic peptide with GSH/GSSH yielded two major products (Fig. S2B). Partial reduction and LC-MS/MS 
analysis showed that the product in peak 1 has the correctly connected Cys29-Cys46 and Cys34-Cys48 
disulfide bonds (Fig. S3). Subsequent iodine oxidation of this intermediate product led to formation of 
the third disulfide bond between Cys24 and Cys36, thus yielding the monomeric CTD (Fig. S2C).
GeXXA-CTD has nAChR-inhibitory activity. Indeed, the monomeric GeXXA-CTD showed inhibi-
tory activity against human α 9α 10 subtype (IC50 of 2.02 μ M), but had little or no effect on other nAChR 
subtypes (Table 1). In general, the activity of GeXXA-CTD is weaker than that of the full-length dimeric 
α D-GeXXA, making GeXXA-CTD apparently specific to the α 9α 10 subtype. While focusing on this 
subtype, we found that GeXXA-CTD has a 10-fold higher potency on rat α 9α 10 (IC50 of 198 nM) than 
on human α 9α 10 nAChR (Fig. 3A and Table 2). Interestingly, GeXXA-CTD also exhibited a compara-
bly high potency (IC50 of 224 nM) on a hybrid receptor of human α 9 and rat α 10 subunits (hα 9rα 10)17 
(Fig. 3A). These results suggest that the α 10 subunit determines the preference of GeXXA-CTD for rat 
over human α 9α 10 nAChR. Since the nAChR-inhibitory activities of α D-GeXXA and GeXXA-CTD 
were measured after extracellular application (see materials and methods), the species preference might 
be due to residue differences in the extracellular domain of human and rat α 10 subunits.
www.nature.com/scientificreports/
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Identification of the binding site of αD-GeXXA. To investigate the potential binding site of the 
α 9α 10 nAChR for α D-GeXXA, we compared the sequences of the extracellular domains of human 
and rat α 10 subunits and identified differences in 12 residues (Fig. S4). Based on the EM structure of 
Torpedo α 1β 1δ γ nAChR18 and the crystal structures of AChBP12, the corresponding positions of these 
12 differing residues are mostly well scattered on the surface of the extracellular domain (Fig. S5A and 
B). However, the pseudo two-fold symmetry of the two CTDs in the dimeric α D-GeXXA implies exist-
ence of two equivalent binding sites on each nAChR, presumably on two non-adjacent subunits. On the 
other hand, the length of α D-GeXXA (up to 52.4 Å between the Cα atoms of the two C-terminal Met50 
residues) makes it unlikely that α D-GeXXA binds in the nAChR central pore or on the outside-facing 
surface of the pentameric extracellular domains (Fig. S5C). Thus, the top surface of nAChR seems the 
most likely binding site for α D-GeXXA. Among the 12 differing residues, only residue 7 is located on the 
top surface of nAChR. We therefore hypothesized that His7 is the likely candidate conferring specificity 
of α D-GeXXA to rat α 10 subunit.
To verify the functional role of residue 7 of nAChR α 10 subunit in α D-GeXXA binding, we mutated 
Leu7 of human α 10 subunit to His, the corresponding residue in rat α 10 subunit. The inhibitory activity 
of a competitive α -conotoxin Vc1.1 was not affected by this mutation (data not shown), thus exclud-
ing the possibility of the mutation introducing significant structural change. Remarkably, GeXXA-CTD 
Figure 1. Identification and nAChR-inhibitory activities of αD-GeXXA. (A) Separation of a crude 
venom extraction from C. generalis (shown in inset) on a semi-preparative Agilent ZORBAX 300SB-C18 
column. The α D-GeXXA peak is indicated with an asterisk. The elution gradient was 5–55% acetonitrile 
for 0–50 min with a flow rate of 1.5 mL/min. (B) Superimposed ACh-evoked current traces in the absence 
(control) and presence of 300 nM α D-GeXXA (5 min post–incubation). Arrows () indicate ACh 
application (1 s). (C) Concentration-response curves of α D-GeXXA at different nAChR subtypes. Note that, 
for the comparison between the activities of dimeric and monomeric GeXXA, the concentration of dimeric 
α D-GeXXA is calculated as the concentration of single subunit.
www.nature.com/scientificreports/
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showed an IC50 of 183 nM on this hα 9α 10[L7H] mutant. This is comparable to the activity on rα 9α 10 
but is 11-fold lower than that on hα 9α 10 (Fig. 3A and Table 2), strongly suggesting that His7 of rat α 10 
subunit is involved in the interaction with GeXXA-CTD.
To further confirm this potential binding site for α D-conotoxins, the activity of the natural dimeric 
α D-GeXXA was also measured on these nAChR subtypes. The dimeric α D-GeXXA exhibited a strong 
preference on rat α 9α 10 subtype rather than human α 9α 10 subtype, the IC50 on rat α 9α 10 subtype 
(1.2 nM, Fig.  3B and Table  2) being clearly lower than that on human α 9α 10 subtype. Similar to the 
situation of GeXXA-CTD, the dimeric α D-GeXXA showed the same potency on the hybrid receptor of 
human α 9 and rat α 10 subunits (hα 9rα 10), with an IC50 of 1.2 nM (Fig. 3B and Table 2). Furthermore, 
the L7H mutation of human α 10 subtype clearly enhanced the potency of α D-GeXXA, its IC50 on 
hα 9α 10[L7H] getting close to that on rα 9α 10 and hα 9rα 10 (Fig. 3B and Table 2). These results further 
support the notion that His7 of the rat α 10 subunit confers the species preference of α D-GeXXA and 
may serve as the binding site for α D-GeXXA.
A cooperative two-site binding model of αD-GeXXA. Based on sequence alignment, the critical 
residue, His7 of rat α 10 subunit, corresponds to Asn9 of the Torpedo δ subunit or Glu8 of the Torpedo γ 
subunit (Fig. S4), which is located on the complementary (− ) side of each subunit and faces towards the 
principal (+ ) side of its clockwise adjacent subunit (Fig. S5C). Therefore, the binding site of α D-GeXXA 
is probably located at the interface between the α 10 subunit and its clockwise adjacent subunit. In the 
pentameric α 9α 10 nAChR, there are two α 9 and three α 10 subunits19. Following the nomenclature for 
ACh-binding sites on nAChR4, the three α 10-involving interfaces would be two “α 9α 10” interfaces and 
one “α 10α 10” interface, all of which could be potential binding sites for α D-GeXXA. However, the 
pseudo two-fold symmetry and the length of the dimeric full-length α D-GeXXA suggest that the two 
CTDs of this toxin most likely bind the two “α 9α 10” interfaces at the top surface of α 9α 10 nAChR 
(Fig  4). By doing so, α D-GeXXA, and possibly all the α D-conotoxins, can allosterically and coopera-




IC50 (95% CI) Hill Slope (nH) IC50 (95% CI) Hill Slope (nH)
hα 9α 10 28 nM (22–35) − 1.3 2.02 μ M (1.82–2.25) − 1.7
hα 7 210 nM (174–253) − 2.2 − a − 
rα 3β 2 498 nM (407–609) − 3.5 − − 
rα 3β 4 614 nM (491–768) − 1.6 − − 
rα 4β 2 > 3 μ M − − − 
rα 4β 4 > 3 μ M − 0.9 − − 
rα 1β 1δ ε 743 nM (606–911) − 1.6 − − 
Table 1.  Inhibition of different nAChR subtypes by dimeric αD-GeXXA and monomeric GeXXA-CTD. 
aundetectable.
Figure 2. The crystal structure of αD-GeXXA. (A) Crystal structure of α D-GeXXA. The NTDs of two 
monomers are shown in green and pink, and the two CTDs are shown in cyan and magenta, respectively. 
Disulfide bonds are shown in yellow. (B) Sequence and disulfide linkage of α D-GeXXA.
www.nature.com/scientificreports/
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This cooperative, two-site binding model of α D-GeXXA is also supported by our electrophysiological 
data. Firstly, inhibition of nAChR by both α D-GeXXA and GeXXA-CTD often gave Hill slopes greater 
than 1 (Tables  1 and 2), suggesting cooperative rather than single-site binding on nAChR. Secondly, 
the dimeric α D-GeXXA is considerably more potent than the monomeric GeXXA-CTD (Table  1 and 
Fig.  3). Thirdly, the dimeric α D-GeXXA exhibits much slower dissociation kinetics than the mono-
meric GeXXA-CTD (Fig.  3C,D). Interestingly, all these properties have been observed in a study of 
Figure 3. The nAChR-inhibitory activities and different dissociation kinetics of monomeric GeXXA-CTD 
and dimeric αD-GeXXA. (A) Concentration-response curves of GeXXA-CTD at human α 9α 10 (•), rat 
α 9α 10 (), hybrid hα 9rα 10 (◊) and human α 9α 10[L7H] () receptors. (B) Concentration-response curves 
of α D-GeXXA at human α 9α 10 (•), rat α 9α 10 ( ), hybrid hα 9rα 10 (◊) and human α 9α 10[L7H] (). 
(C,D) GeXXA-CTD (10 μ M) (Panel C) has faster washout kinetics when compared to α D-GeXXA (300 nM) 
(Panel D) at hα 9α 10 nAChR expressed in Xenopus oocytes. Arrows ()indicate ACh application (1 s).
α9α10 nAChR 
GeXXA-CTD αD-GeXXA
IC50 (95% CI) Hill Slope (nH) IC50 (95% CI) Hill Slope (nH)
hα 9α 10 2.02 μ M (1.82–2.25) − 1.7 28 nM (22–35) − 1.3
rα 9α 10 198 nM (164–238) − 1.7 1.2 nM (1.0–1.4) − 1.9
hα 9rα 10 224 nM (194–258) − 1.4 1.1 nM (0.9–1.3) − 1.6
hα 9α 10[L7H] 183 nM (132–255) − 2.8 3.3 nM (2.8–3.8) − 3.6
Table 2.  Inhibitory activities of monomeric GeXXA-CTD and dimeric αD-GeXXA on α9α10 nAChR 
from different species.
www.nature.com/scientificreports/
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polymer-linked ligand dimers20. We now show that this dimerization strategy is adopted by a natural 
toxin to gain higher potency.
In summary, by resolving the crystal structure and performing structure-guided dissection of a dimeric 
conotoxin α D-GeXXA, we demonstrate that α D-conotoxins inhibit nAChR most likely by binding of 
the two CTDs cooperatively to two inter-subunit interfaces on the top surface of nAChR. This work-
ing mechanism is distinct from that of another dimeric conotoxin that targets AMPA receptors21. The 
binding site of α D-conotoxin on nAChR differs from the binding sites of the endogenous ligand ACh, 
and the competitive α -conotoxins12,13 and α -bungarotoxin22. However, the binding site stoichiometry of 
α D-GeXXA is coincidently the same as that of ACh on the muscle subtype and neuronal heterogene-
ous nAChR (that is, 2 of 5 inter-subunit interfaces)23 (Fig. 4). The cooperative inhibitory mechanism of 
α D-GeXXA via a novel binding site on nAChRs provides a valuable basis for the rational design of new 
nAChR-targeting drugs.
Methods
Toxin purification and characterization. Conus generalis specimens were collected from the South 
China Sea. To extract the crude venom, the venom duct of living snails was dissected into short frag-
ments and venom was extracted successively with 0.1% (v/v) trifluoroacetic acid (TFA), and 0.1% TFA 
in 20%, 30%, 40% and 50% acetonitrile. Supernatants were pooled and lyophilized.
For toxin purification, the lyophilized crude venom was dissolved in 0.1% TFA, and the soluble super-
natant was separated on a Zobax C18 column (250 × 4.6 mm, Agilent) with an acetonitrile gradient using 
an Agilent 1100 HPLC system. Reduction of the purified α D-GeXXA was carried out in 100 mM Tris-HCl, 
pH 8.7, 2 mM EDTA and a 100-fold excess of dithiothreitol (DTT) at 37 °C for 1 h. Alkylation of the reduced 
thiol groups of α D-GeXXA was carried out in the same buffer containing 10 mM N-ethylmaleimide 
(NEM) at 37 °C in the dark for 0.5 h. After being purified on a C18 HPLC column (Fig. S1), the reduced 
and alkylated α D-GeXXA was applied to an ABI 491A Procise Protein Sequencing System for N-terminal 
sequencing. The N-terminal partial sequence DVHRPCQSVRPGRVWGKCCLT was obtained.
cDNA cloning. Total RNA was extracted from homogenized venom ducts of Conus generalis with 
TRIZOL reagent, according to the manufacturer’s protocol. The 3′ -partial cDNA of α D-GeXXA was cloned 
using a 3′ -RACE kit (Invitrogen) and a gene specific primer 1 (5′ -GAYGTNCAYCGNCCNTGYCAR-3′ , 
Y: T/C, R: G/A, N: A/T/G/C), encoding α D-GeXXA N-terminal sequence DVHRPCQ. The 5′ -partial 
cDNA of α D-GeXXA was cloned using a 5′ -RACE kit (Takara) with gene specific primers (GSP2: 
5′ -GATTGCACTCAGGCAGATCA-3′ ; GSP3: 5′ - CGGTTGCTCTTTGAT TGGTT-3′ ; GSP4: 
5′ -CATTACGCAGGAACACCCGTG-3′ ) based on the 3′ -partial cDNA sequence. Overlapping of the 
3′ - and 5′ -partial cDNA sequences gave the full-length cDNA of α D-GeXXA (Fig. S1D).
Electrophysiological recordings from nAChRs exogenously expressed in Xenopus 
oocytes. RNA preparation, oocyte preparation, and expression of nAChR subunits in Xenopus oocytes 
were performed as described previously24. Briefly, plasmids with cDNAs encoding the rat α 1, α 3, α 4, α 9, 
α 10, β 1, β 2, β 4, δ , ε and human α 7 subunits subcloned into the oocyte expression vector pNKS2 and 
human α 9 and α 10 subunits subcloned into the pT7TS vector were used for mRNA preparation using 
the mMESSAGE mMACHINE Kit (Ambion Inc., USA). All oocytes were injected with 5 ng of cRNA and 
kept at 18 °C in ND96 buffer (96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 5 mM HEPES, 
pH 7.4), supplemented with 50 mg/L gentamycin and 100 μ g/ml penicillin/streptomycin for 2–5 days 
before recording. Membrane currents were recorded from Xenopus oocytes using a GeneClamp 500B 
amplifier (Molecular Devices) in a two-electrode (virtual ground circuit) voltage-clamp setup. Both the 
voltage-recording and current-injecting electrodes were pulled from borosilicate glass (GC150T - 7.5, 
Figure 4. Binding model of αD-GeXXA on nAChR. (A) The well-established binding site stoichiometry 
of ACh on the muscle nAChR subtype. (B) Binding model of α D-GeXXA on the α 9α 10 subtype of nAChR. 
The two CTDs of α D-GeXXA, which are shown in cyan and pink, respectively, with roughly 180° rotation, 
bind at the top surface of the two “α 9α 10” interfaces to inhibit the opening of the nAChR.
www.nature.com/scientificreports/
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Harvard Apparatus Ltd.) and had resistances of 0.3–1.5 MΩ when filled with 3 M KCl. All recordings 
were conducted at room temperature (21–23 °C) using a bath solution of ND96 as described above. 
During recording, the oocytes were perfused continuously at a rate of 1.5 ml/min, with 300 s incubation 
times for peptides. Acetylcholine (200 μ M for α 7 and 50 μ M for all other nAChR subtypes) was applied 
for 1 s at 2 ml/min, with 3–4 min washout periods between applications. Cells were voltage-clamped at 
a holding potential of − 80 mV. Data were filtered at 100 Hz and sampled at 500 Hz. Peak ACh-evoked 
current amplitude was measured before and after incubation with peptide.
Concentration-response curves for antagonists were fitted by unweighted nonlinear regression to the 
following logistic equation 1




where Ex is the response, X is the antagonist concentration, Emax is the maximal response, nH is the 
slope factor, and IC50 is the antagonist concentration giving 50% inhibition of maximal response. All 
electrophysiological data were pooled (n = 4–8 oocytes for each data point) and represent arithmetic 
means ± standard error of the fit. Computation was done using GraphPad Prism 6 (GraphPad Software 
Inc., La Jolla, CA, USA).
Crystallization and structure determination. The powder of 1.0 mg native α D-GeXXA was dis-
solved in a buffer containing 20 mM Tris-HCl (pH 8.0) and 100 mM NaCl. Crystallization of α D-GeXXA 
was performed using the hanging drop vapor diffusion method by mixing 1.5 μ l protein solution (about 
10 mg/ml) and 1.5 μ l reservoir solution at 16 °C. Crystals were grown from drops consisting of a reservoir 
solution of 0.1 M citrate acid (pH 5.0) and 10% PEG 6000 after about 1 week. The diffraction data were 
processed, integrated, and scaled together as two datasets with HKL200025. Dataset 1 was processed at high 
resolution for ab initio phasing and dataset 2 with reasonable statistics was used for structure refinement.
The structure of α D-GeXXA was determined by ab initio methods using the program Acorn15. Phases 
were determined with dataset 1 by setting optimal Acorn parameters to start from a random atom (no 
prior knowledge) to determine substructure and then applied to the program Acorn-MR to produce 
an interpretable electron density map. An initial model of 63 out of 100 residues for two monomers 
was constructed automatically by warpNtrace mode of ARP/wARP26. The remaining residues and addi-
tional water molecules were built manually using Coot with dataset 2 27,28. Structure refinement was 
performed using Refmac5 and Phenix27,29. The stereochemistry of the protein model was analyzed using 
MolProbity30. Structure analysis was carried out using programs in CCP431. Figures were generated using 
Pymol (http://www.pymol.org). Statistics of the structure refinement and the quality of the final structure 
model are summarized in Table S1.
Preparation of GeXXA-CTD. The linear peptide of GeXXA-CTD, with Cys24 and Cys36 protected 
by Acm, was synthesized by the Chinese Peptide Company (Hangzhou, China). The peptide was first 
oxidized with 1 mM GSSG/GSH (Fig. S2), which produced two products. To examine the disulfide 
linkage, the first peak (Peak 1) was partially reduced with Tris(2-carboxyethyl)phosphine (TCEP) and 
alkylated with NEM, and then fully reduced with DTT and alkylated with iodoacetamide (IAA). The 
resultant product of Peak 1 was digested with trypsin and analyzed with LC-MS/MS on an Orbitrap 
Elite (ThermoFisher, USA), revealing the Cys29-Cys46 and Cys34-Cys48 linkages (Fig. S3). Peak 1 was 
then treated with iodine to remove the Acm group and oxidize the disulfide bond between Cys24 and 
Cys36 (Fig. S2).
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